Literature DB >> 3909096

Cisplatin: a review of clinical applications and renal toxicity.

D T Sleijfer, S Meijer, N H Mulder.   

Abstract

In reviewing the literature about the clinical application of cis-diamminedichloroplatinum(II) (cisplatin) it can be concluded that the availability of cisplatin has been an important advance in cancer chemotherapy; especially in patients with disseminated testicular carcinoma and ovarian cancer cisplatin-based combinations are the first choice treatment. Our own investigations of the nature of the main form of toxicity of cisplatin, the nephrotoxicity, are mentioned and methods of its prevention are summarized.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3909096     DOI： 10.1007/bf01959196

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN： 0167-6555


  82 in total

1.  Anaphylactic reactions to repeated intravesical instillation with cisplatin.

Authors:  L Denis
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

2.  Etoposide and cis-platinum in non-small-cell bronchogenic carcinoma.

Authors:  J Klastersky; E Longeval; C Nicaise; D Weerts
Journal:  Cancer Treat Rev       Date:  1982-06       Impact factor: 12.111

3.  The measurement of glomerular filtration rate and effective renal plasma flow in man by iothalamate 125-I and iodopyracet 131-I.

Authors:  C M Elwood; E M Sigman
Journal:  Circulation       Date:  1967-09       Impact factor: 29.690

4.  Coordination complexes of platinum as antitumor agents.

Authors:  R J Speer; H Ridgway; L M Hall; D P Stewart; K E Howe; D Z Lieberman; A D Newman; J M Hill
Journal:  Cancer Chemother Rep       Date:  1975 May-Jun

5.  Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.

Authors:  J P Neijt; W W ten Bokkel Huinink; M E van der Burg; A T van Oosterom; R Vriesendorp; H M Pinedo
Journal:  Radiother Oncol       Date:  1984-06       Impact factor: 6.280

6.  Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin.

Authors:  R L Schilsky; T Anderson
Journal:  Ann Intern Med       Date:  1979-06       Impact factor: 25.391

7.  Vinblastine, infusion, bleomycin, and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma.

Authors:  L Nathanson; S D Kaufman; R W Carey
Journal:  Cancer       Date:  1981-09-15       Impact factor: 6.860

8.  Cis-platinum induction chemotherapy in the multi-modality initial treatment of advanced stage IV carcinoma of the head and neck.

Authors:  S D Schaefer; R Middleton; J Reisch; E P Frenkel
Journal:  Cancer       Date:  1983-06-15       Impact factor: 6.860

9.  A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck.

Authors:  W K Hong; S Schaefer; B Issell; C Cummings; D Luedke; R Bromer; S Fofonoff; J D'Aoust; S Shapshay; J Welch; E Levin; M Vincent; C Vaughan; S Strong
Journal:  Cancer       Date:  1983-07-15       Impact factor: 6.860

10.  Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin.

Authors:  R M York; D H Lawson; J McKay
Journal:  Cancer       Date:  1983-12-15       Impact factor: 6.860
View more
  12 in total

1.  Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.

Authors:  Iryna A Khasabova; Sergey Khasabov; Justin Paz; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

2.  Ultrasound image-guided therapy enhances antitumor effect of cisplatin.

Authors:  Noboru Sasaki; Nobuki Kudo; Kensuke Nakamura; Sue Yee Lim; Masahiro Murakami; W R Bandula Kumara; Yu Tamura; Hiroshi Ohta; Masahiro Yamasaki; Mitsuyoshi Takiguchi
Journal:  J Med Ultrason (2001)       Date:  2013-07-17       Impact factor: 1.314

3.  The protective effect of royal jelly against cisplatin-induced renal oxidative stress in rats.

Authors:  Sibel Silici; Oguz Ekmekcioglu; Murat Kanbur; Kemal Deniz
Journal:  World J Urol       Date:  2010-04-06       Impact factor: 4.226

4.  Caveolin-1 sensitizes cisplatin-induced lung cancer cell apoptosis via superoxide anion-dependent mechanism.

Authors:  Kanittha Pongjit; Pithi Chanvorachote
Journal:  Mol Cell Biochem       Date:  2011-07-15       Impact factor: 3.396

Review 5.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

6.  HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer.

Authors:  Yanbin Liu; Amanda M Bernauer; Christin M Yingling; Steven A Belinsky
Journal:  Carcinogenesis       Date:  2012-03-31       Impact factor: 4.944

7.  Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.

Authors:  Chih-Wen Tseng; Chien-Fu Hung; Ronald D Alvarez; Cornelia Trimble; Warner K Huh; Daejin Kim; Chi-Mu Chuang; Cheng-Tao Lin; Ya-Chea Tsai; Liangmei He; Archana Monie; T-C Wu
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

8.  A biocompatible in vivo ligation reaction and its application for noninvasive bioluminescent imaging of protease activity in living mice.

Authors:  Aurélien Godinat; Hyo Min Park; Stephen C Miller; Ke Cheng; Douglas Hanahan; Laura E Sanman; Matthew Bogyo; Allen Yu; Gennady F Nikitin; Andreas Stahl; Elena A Dubikovskaya
Journal:  ACS Chem Biol       Date:  2013-03-29       Impact factor: 5.100

Review 9.  A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity.

Authors:  Zahra Nasiri-Toosi; Simin Dashti-Khavidaki; Hossein Khalili; Mahboob Lessan-Pezeshki
Journal:  Eur J Clin Pharmacol       Date:  2012-11-22       Impact factor: 2.953

Review 10.  Cancer risk from inorganics.

Authors:  S H Swierenga; J P Gilman; J R McLean
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.